$RLAY

Rahmer Peter sold $14K of RLAY

Rahmer Peter (See remarks) sold 748 shares of Relay Therapeutics, Inc. (RLAY) at $18.61 on 2026-07-28.

Original reporting
SEC EDGAR · Rahmer Peter
Published Jul 30, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:10 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$RLAY
Neutral
low confidence
Mentioned
$RLAY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RLAYNeutralLow
01

Why it matters

An officer open-market sale was reported, but the disclosure does not include any new company-specific performance, guidance, or regulatory/clinical catalyst.

02

Market read

Traders may note insider selling as a minor sentiment datapoint, but there is no actionable fundamental change in the text.

03

What to watch

No 10b5-1 plan is noted, but the filing also lacks context (taxes, diversification, planned expenses), limiting interpretability.

Relevance 3/10Novelty 2/10Timing: filed 2026-07-30, transaction dated 2026-07-28

Background

The article is an SEC Form 4 insider transaction disclosure for Relay Therapeutics, Inc.

Company-level read

Ticker impact

$RLAYNeutralLow confidence
Context

Relay Therapeutics Form 4 shows officer Rahmer Peter sold 748 shares at $18.61 on 2026-07-28, totaling about $13.9K.

Expected impact

Likely limited near-term impact; any effect would be small and short-lived unless followed by additional disclosures.

Evidence & confidence

The transaction size is small relative to a typical public-company float, and the filing provides no new operational or financial catalyst.

Market effects

No clear sector read-through from a small, routine insider sale.

None.

None.

Counterpoint

The sale may be for personal liquidity needs and does not necessarily signal reduced confidence, especially without any accompanying negative company news.

Key entities

  • Relay Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Rahmer Peter

    Officer who sold 748 shares at $18.61 on 2026-07-28.

Related articles

$RLAYMed

Relay Therapeutics, Inc. (RLAY): Results of Operations and Financial Condition

Relay Therapeutics, Inc. (RLAY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 4 rlay-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine-sensitive patient

$RLAYLowAI 8/10

Relay Therapeutics Shares Jump 18%

Relay Therapeutics’ shares (RLAY) rose 18.21% to $16.86 on Tuesday, up $2.60 from the prior close of $14.26 on the Nasdaq, despite no company-specific news. The stock traded between $16.04 and $17.47 and volume increased to 4,545,643 shares versus a 3,532,352 daily average. The 52-week range is $2.98–$17.47.